STAT+: Trump administration launches probe into pharmaceutical imports
The Trump administration disclosed that it had formally opened an investigation into the extent to which the importation of certain pharmaceuticals may threaten national security.
The Trump administration disclosed Monday that it had formally opened an investigation into the extent to which the importation of certain pharmaceuticals may threaten national security, a move that is a widely anticipated prelude to imposing tariffs on a potentially large number of medicines.
In a Federal Register notice, the U.S. Department of Commerce noted the so-called 232 investigation actually began on April 1 and encompasses not only medicines, but also active pharmaceutical ingredients and key starting materials, as well as derivative products.
President Trump has already indicated that tariffs on pharmaceuticals are expected in the coming weeks.
